EZH2 and hepatocellular carcinoma: Acquisition of resistance to infigratinib, a promising FGFR inhibitor used to treat HCC, was associated with elevated HER2 and HER3 levels along with increased enhancer of zeste homolog 2 (EZH2) expression [239].